Table 2.
Mineral metabolism parameters and biomarkers of bone turnover of patients with CAVD and controls
| Variable | Controls (n=164) | Patients with AVSc (n=164) | Patients with AVS (n=96) | P 1 | P 2 |
| Mineral metabolism parameters | |||||
| Serum calcium (mg/dl) | 8.39±0.44 | 8.79±0.33 | 9.11±0.57 | <0.001 | <0.001 |
| Serum phosphate (mg/dl) | 3.06±0.54 | 3.75±0.57 | 4.38±1.05 | <0.001 | <0.001 |
| iPTH (pg/ml) | 37.88±13.11 | 55.97±17.96 | 76.12±33.72 | <0.001 | <0.001 |
| 25-OHD (nmol/L) | 58.48±20.80 | 39.27±16.31 | 32.32±18.58 | <0.001 | <0.001 |
| AKP (U/L) | 52.58±15.69 | 70.48±24.63 | 82.40±26.51 | <0.001 | <0.001 |
| Biomarkers of bone turnover | |||||
| Serum osteocalcin (ng/ml) | 11.80±4.33 | 18.45±8.19 | 21.76±9.53 | <0.001 | <0.001 |
| Serum PINP (ng/ml) | 30.94±13.67 | 45.24±17.01 | 59.33±32.98 | <0.001 | <0.001 |
| Serum β-CTx (ng/ml) | 0.32±0.16 | 0.50±0.19 | 0.67±0.35 | <0.001 | <0.001 |
Data are expressed as mean±SD. iPTH: intact parathyroid hormone; 25-OHD: 25-hydroxyvitamin D; AKP: alkaline phosphatase; PINP: procollagen I N-terminal peptide; β-CTx: β-isomerized type I collagen C-telopeptide breakdown products; CAVD: calcific aortic valve disease; AVSc: aortic valve sclerosis; AVS: aortic valve stenosis. P 1: control group vs. patients with AVSc; P 2: patients with AVSc vs. those with AVS